Skip to content
10-Q

Quarterly Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-000128

← back to feed
Filed
Jan 23, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Jan 19, 2026 207.03M sh
Current Liabilities Q2 2024 · Jul 31, 2023 $3.38M
Current Liabilities Q2 2024 · Jan 31, 2023 $3.07M
Total Liabilities Q2 2024 · Jul 31, 2023 $3.38M
Total Liabilities Q2 2024 · Jan 31, 2023 $3.16M
Current Assets Q2 2024 · Jul 31, 2023 $188.09K
Current Assets Q2 2024 · Jan 31, 2023 $437.08K
Total Assets Q2 2024 · Jul 31, 2023 $404.91K
Total Assets Q2 2024 · Jan 31, 2023 $765.95K
Gross Profit Q2 2024 · Jul 31, 2023 $0
Gross Profit Q2 2024 · Jul 31, 2023 $0
Gross Profit Q2 2024 · Jul 31, 2022 $0
Gross Profit Q2 2024 · Jul 31, 2022 $568K
Cost Of Revenue Q2 2024 · Jul 31, 2023 $0
Cost Of Revenue Q2 2024 · Jul 31, 2023 $0
Cost Of Revenue Q2 2024 · Jul 31, 2022 $0
Cost Of Revenue Q2 2024 · Jul 31, 2022 $922K
Shares Diluted Q2 2024 · Jul 31, 2022 206.52M sh
Shares Diluted Q2 2024 · Jul 31, 2022 206.52M sh
Operating Cash Flow restated Q2 2024 · Jul 31, 2022 −$85.62K
Stockholders Equity Q2 2024 · Jul 31, 2022 $1.78M
Stockholders Equity Q2 2024 · Apr 30, 2022 $1.89M
Stockholders Equity Q2 2024 · Jan 31, 2022 $1.58M
Eps Diluted Q2 2024 · Jul 31, 2022 $0.00
Eps Diluted Q2 2024 · Jul 31, 2022 $0.00
Sga Expense restated Q2 2024 · Jul 31, 2022 $174.51K
Sga Expense Q2 2024 · Jul 31, 2022 $399.38K
Net Income restated Q2 2024 · Jul 31, 2022 −$144.14K
Net Income restated Q2 2024 · Jul 31, 2022 $132.52K
Net Income Q2 2024 · Apr 30, 2022 $276.66K
Operating Income restated Q2 2024 · Jul 31, 2022 −$174.51K
Operating Income Q2 2024 · Jul 31, 2022 $168.62K
Revenue Q2 2024 · Jul 31, 2022 $0
Revenue Q2 2024 · Jul 31, 2022 $1.49M